The anticipated world-wide prevalence of diabetes mellitus (DM), will likely be affected, resulting in significant economic and social hardships. There is a cumulative observational evidence linking DM to cirrhosis. DM, NAFLD and metabolic syndrome, are likely perpetrators in progressive cirrhosis and hepatic fibrosis.

Cumulative evidence from previous research recommends that diabetes insulin resistance, and serum glucose are associated with progression of hepatic fibrosis in patients with chronic liver disease. As per a multivariate analysis conducted in 2001, fibrosis was significantly more likely in patients with DM.  In a retrospective study of 1365 patients with biopsy-proven NAFLD, it was discovered that increases in prevalence of DM and degree of fibrosis paralleled each other. DM was also considered as a noteworthy risk factor for advanced fibrosis in patients. Therefore, increases in both are expected to climb.

In addition, the potential effects of antidiabetic drug class/dosage or duration of DM on the risk of cirrhosis need to be further studied to better define the relation between DM and cirrhosis of various etiologies. Growth of cirrhosis is two- to threefold greater in patients with DM, and in this setting, the prevalence of cirrhosis is rolling globally.

Source: Biomed Res Int. 2019